Free Trial
NYSE:DHR

Danaher (DHR) Stock Price, News & Analysis

$274.13
+4.04 (+1.50%)
(As of 07/26/2024 ET)
Today's Range
$271.38
$277.72
50-Day Range
$239.25
$274.13
52-Week Range
$182.09
$277.72
Volume
2.81 million shs
Average Volume
2.92 million shs
Market Capitalization
$197.98 billion
P/E Ratio
46.46
Dividend Yield
0.39%
Price Target
$276.88

Danaher MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
1.0% Upside
$276.88 Price Target
Short Interest
Healthy
0.97% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.36
Upright™ Environmental Score
News Sentiment
0.44mentions of Danaher in the last 14 days
Based on 71 Articles This Week
Insider Trading
Selling Shares
$21.80 M Sold Last Quarter
Proj. Earnings Growth
14.08%
From $7.60 to $8.67 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.72 out of 5 stars

Multi-Sector Conglomerates Sector

3rd out of 20 stocks

Process Control Instruments Industry

4th out of 13 stocks

DHR stock logo

About Danaher Stock (NYSE:DHR)

Danaher Corporation, founded in 1984 by brothers Stephen and Mitchell Rales, is a globally diversified conglomerate headquartered in Washington, D.C. The company has evolved into a major player across various industries, offering a wide range of products and services in the medical, industrial, and commercial sectors. Danaher's mission is to innovate and provide high-quality solutions that positively impact people's lives worldwide. Danaher's began in 1984 as a Massachusetts real estate investment trust called DMG, Inc. The company underwent several reorganizations and strategic acquisitions, culminating in its present-day structure and diverse product portfolio.

Danaher is involved in designing, manufacturing, and marketing a broad array of products and services. Its offerings span medical diagnostics equipment, life sciences and diagnostics tools, environmental solutions, water quality analysis systems, industrial automation tools, and other specialized instruments. Danaher's mission is to leverage its technological expertise and commitment to continuous improvement to develop innovative solutions that enhance human well-being and drive sustainable growth.

The company's diverse product portfolio includes cutting-edge medical diagnostic devices, scientific instruments used in research and healthcare settings, water quality monitoring systems, and automation equipment for industrial applications. Danaher caters to various markets, including healthcare, life sciences, diagnostics, environmental monitoring, and industrial automation. Its products and services find applications in research institutions, healthcare facilities, industrial manufacturers, and government organizations.

Danaher Corporation boasts a leadership team comprising highly accomplished individuals with diverse expertise, driving the company's success and strategic direction. At the helm is Steven M. Rales, the Co-Founder and Chairman, who played a pivotal role in establishing Danaher and has been instrumental in shaping its strategic vision. With his visionary approach, Rales has steered the company towards sustained growth and innovation. Rainer M. Blair holds the positions of President, Chief Executive Officer, and Director, leading Danaher's day-to-day operations and spearheading its growth strategies. Blair's dynamic leadership has been crucial in driving the company's expansion and ensuring its position as a market leader.

Danaher has displayed excellent financial performance in recent years, with consistent revenue growth and profitability. The company's financial stability and strategic acquisitions have contributed to its robust performance. Danaher's strong financials indicate its ability to generate revenue and profits, which has positively influenced investor sentiment and contributed to its favorable valuation.

Danaher's valuation metrics demonstrate positive investor sentiment and confidence in the company's future growth prospects. Its favorable price-to-earnings ratio and price-to-cash flow ratio reflect investor willingness to pay a premium for its earnings potential and cash generation capacity. Danaher's stock performance has been noteworthy, driven by its strong financials, strategic initiatives, and positive market sentiment.

Investors should closely monitor any recent news or events that may have impacted Danaher's share price, such as industry developments or major acquisitions. Danaher operates in diverse industries with various competitors. Its competitive advantages, including a broad product portfolio and emphasis on innovation, position it well within its industries.

Danaher has ample growth opportunities, including expansion into emerging markets, strategic acquisitions, and research and development investments. The company's strong focus on continuous improvement and customer-centric solutions will drive its pursuit of growth opportunities.

Danaher faces potential risks and challenges, including market fluctuations, regulatory changes, and economic uncertainties. However, its proactive risk management strategies mitigate potential impacts on the company's financial performance.

DHR Stock Price History

DHR Stock News Headlines

Danaher (NYSE:DHR) Price Target Raised to $285.00 at Barclays
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
Danaher (NYSE:DHR) PT Raised to $250.00 at Stifel Nicolaus
Q3 2024 EPS Estimates for Danaher Co. Reduced by Analyst (NYSE:DHR)
Brace Yourself: Experts calling for Bitcoin to hit $100k
For the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.
TD Cowen Increases Danaher (NYSE:DHR) Price Target to $310.00
Danaher (NYSE:DHR) Given New $280.00 Price Target at SVB Leerink
Danaher (NYSE:DHR) Price Target Raised to $275.00 at Bank of America
Danaher (NYSE:DHR) Price Target Raised to $278.00 at Robert W. Baird
Stifel Nicolaus Reaffirms Their Hold Rating on Danaher (DHR)
Demystifying Danaher: Insights From 5 Analyst Reviews
Danaher (NYSE:DHR) PT Raised to $250.00
See More Headlines
Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 7/26 Dividend
6/28/2024
Last Earnings
7/23/2024
Today
7/26/2024
Dividend Payable
7/26/2024
Next Earnings (Estimated)
10/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Process control instruments
Sub-Industry
Industrial Conglomerates
CUSIP
23585110
Employees
63,000
Year Founded
1984

Price Target and Rating

Average Stock Price Target
$276.88
High Stock Price Target
$310.00
Low Stock Price Target
$247.00
Potential Upside/Downside
+1.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
17 Analysts

Profitability

Net Income
$4.76 billion
Pretax Margin
19.07%

Debt

Sales & Book Value

Annual Sales
$23.89 billion
Cash Flow
$10.92 per share
Book Value
$69.10 per share

Miscellaneous

Free Float
658,471,000
Market Cap
$197.83 billion
Optionable
Optionable
Beta
0.83

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Should I Buy Danaher Stock? DHR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Danaher Co.:

  • Danaher has received multiple "buy" ratings from equities research analysts, indicating positive market sentiment towards the company.
  • The company's CEO and CFO have been actively selling shares at higher prices, suggesting confidence in the company's future performance.
  • Recent insider activity shows that company insiders own a significant portion of Danaher's stock, aligning their interests with shareholders.
  • Despite a slight decrease in stock price, Danaher's 50-day moving average price is higher than its 200-day moving average, indicating potential upward momentum.
  • The consensus price target for Danaher is $269.29, suggesting potential for stock price appreciation based on analyst projections.

Cons

Investors should be bearish about investing in Danaher Co. for these reasons:

  • Some analysts have given a "neutral" rating to Danaher, indicating a mixed outlook on the company's future performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these Danaher pros and cons to contact@marketbeat.com.

DHR Stock Analysis - Frequently Asked Questions

How have DHR shares performed this year?

Danaher's stock was trading at $231.34 at the beginning of the year. Since then, DHR shares have increased by 18.5% and is now trading at $274.13.
View the best growth stocks for 2024 here
.

How were Danaher's earnings last quarter?

Danaher Co. (NYSE:DHR) released its quarterly earnings data on Tuesday, July, 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The company's quarterly revenue was down 2.9% on a year-over-year basis.
Read the conference call transcript
.

What is Rainer M. Blair's approval rating as Danaher's CEO?

27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Does Danaher have any subsidiaries?

Danaher subsidiaries include these companies: Aldevron, Precision NanoSystems, Aquatic Informatics, Cytiva, GE Biopharma, Integrated DNA Technologies, IDBS Group, and more.

Who are Danaher's major shareholders?

Top institutional investors of Danaher include Bank of New York Mellon Corp (1.16%), Swedbank AB (0.35%), Sumitomo Mitsui Trust Holdings Inc. (0.26%) and Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.23%). Insiders that own company stock include Alan G Spoon, Rainer Blair, Joakim Weidemanis, Linda Filler, Daniel Raskas, Matthew Mcgrew, Robert S Lutz, Brian W Ellis, Teri List, Walter G Lohr, Raymond C Stevens, Jennifer Honeycutt, Jose-Carlos Gutierrez-Ramos, Georgeann Couchara, Linda P Hefner, Mitchell P Rales, Elias A Zerhouni, Angela S Lalor and Angela S Lalor.
View institutional ownership trends
.

How do I buy shares of Danaher?

Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Danaher own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC) and Alibaba Group (BABA).

This page (NYSE:DHR) was last updated on 7/26/2024 by MarketBeat.com Staff

From Our Partners